Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Withdrawn 1Completed 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2NET 1

Conditions

Neuroendocrine Tumors 14Carcinoid Tumor 5Gastro-enteropancreatic neuroendocrine tumor 4Acromegaly 3Serotonin Syndrome 2Pituitary Neoplasms 2Pheochromocytoma 1Paraganglioma 1Neuroendocrine Tumour With Carcinoid Symptoms 1Neuroendocrine Tumors in Lung 1Neoplastic Cells, Circulating 1Neoplasm Metastasis 1Growth Hormone-Secreting Pituitary Adenoma 1Gigantism 1Gastrointestinal Neoplasms 1Flushing 1Diarrhea 1Carcinoma, Hepatocellular 1Carcinoid Heart Disease 1Adenoma, Islet Cell 1

Interventions

telotristat ethyl 3lanreotide 2pasireotide 1lutetium Lu 177 dotatate 1Receptor-Like Protein Tyrosine Phosphatases, Class 2 1Random Allocation 1Panitumumab 1Octreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Serotonin Syndrome × lanreotide × Endocrine × Clear all
NCT00774930 2022-10-14

ELECT

Ipsen

Phase 3 Completed
115 enrolled 17 charts
EndocrineNET

Carcinoid Tumor, Diarrhea, Flushing, Neuroendocrine Tumors, Serotonin Syndrome

NCT04065165 2020-02-05

TELEFIRST

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Withdrawn
Endocrine

Carcinoid Heart Disease, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡